These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 19379170

  • 1. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I, Balon BP, Rus I, Marc J.
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease.
    Siomou E, Challa A, Printza N, Giapros V, Petropoulou F, Mitsioni A, Papachristou F, Stefanidis CJ.
    Pediatr Nephrol; 2011 Jul; 26(7):1105-14. PubMed ID: 21479768
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients.
    Mesquita M, Wittersheim E, Demulder A, Dratwa M, Bergmann P.
    Adv Perit Dial; 2005 Jul; 21():181-4. PubMed ID: 16686314
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis.
    Ambroszkiewicz J, Sands D, Gajewska J, Chelchowska M, Laskowska-Klita T.
    Adv Med Sci; 2013 Jul; 58(2):338-43. PubMed ID: 24277958
    [Abstract] [Full Text] [Related]

  • 16. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
    Crisafulli A, Romeo A, Floccari F, Aloisi E, Atteritano M, Cincotta M, Aloisi C, Pizzoleo MA, Ruello A, Artemisia A, Valenti A, Frisina N, Teti D, Buemi M.
    Ren Fail; 2005 Jul; 27(5):531-9. PubMed ID: 16152990
    [Abstract] [Full Text] [Related]

  • 17. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C, Gourgiotis D, Kossiva L, Doulgeraki A, Marmarinos A, Galli-Tsinopoulou A, Karavanaki K.
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.
    Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Tziamalis MP, Stathakis CP, Diamanti-Kandarakis E, Dimitroulis D, Perrea DN.
    J Bone Miner Metab; 2008 Apr; 26(1):66-72. PubMed ID: 18095066
    [Abstract] [Full Text] [Related]

  • 20. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
    Evans CE, Mylchreest S, Andrew JG.
    BMC Musculoskelet Disord; 2006 Mar 06; 7():21. PubMed ID: 16519799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.